Core Viewpoint - The major shareholder of Zhongke Soft Technology Co., Ltd. plans to reduce its shareholding due to the research needs of the Institute of Software, Chinese Academy of Sciences, without changing the control of the company [2][3]. Shareholder Reduction Plan - As of the announcement date, the major shareholder, Beijing Kesoft Chuangyuan Software Technology Co., Ltd., holds 194,847,206 shares, accounting for approximately 23.45% of the total shares [2]. - The reduction plan involves selling up to 16,620,800 shares, which is no more than 2% of the total share capital, within three months after the announcement [2]. - The shares will be reduced through centralized bidding and block trading, with each method limited to 8,310,400 shares, or 1% of the total shares [2]. Use of Proceeds - The funds obtained from the share reduction will primarily be used for the research and development of the Institute of Software [5]. Shareholder Commitment - The major shareholder has made commitments regarding the holding period and methods of share reduction, including compliance with relevant regulations and gradual reduction after the lock-up period [6][7]. - If the shareholder fails to fulfill the reduction commitment, they will publicly explain the reasons and apologize to shareholders and the public [7]. Additional Information - The reduction plan will be adjusted if there are changes in the company's shares due to stock dividends, capital increases, or other events [2]. - The implementation of the reduction plan will not lead to a change in the control of Zhongke Soft [9].

Group 1 - The company Skyworth Digital (000810) announced that its chairman, Shi Chi, plans to reduce his holdings by no more than 9 million shares, accounting for 0.788% of the total share capital, within three months after 15 trading days from the announcement date [1] - Director and Vice General Manager Zhang Zhi intends to reduce his holdings by no more than 800,000 shares, representing 0.070% of the total share capital [1] - Director Shen Yiming plans to reduce his holdings by no more than 90,000 shares, which is 0.008% of the total share capital [1] - Chief Financial Officer Wang Yin intends to reduce his holdings by no more than 70,000 shares, accounting for 0.006% of the total share capital [1] - The reason for the reductions in holdings by all directors is personal financial arrangement needs [1]

证券代码：688158 证券简称：优刻得 公告编号：2025-023 优刻得科技股份有限公司 关于持股5%以上股东持股比例降至5%的 权益变动提示性公告 经营期限 自 2016 年 11 月 09 日至 2076 年 11 月 08 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 本次权益变动为优刻得科技股份有限公司（以下简称"公司"）持股 5% 以上股东履行此前披露的股份减持计划，不触及要约收购； ? 本次权益变动后，股东中移资本控股有限责任公司（以下简称"中移资 本"）持有公司股份数量由 23,537,521 股减少至 22,654,755 股，占公司目前总股 本的比例由本次减持前的 5.19%降至 5.00%； ? 本次权益变动为持股 5%以上非第一大股东减持，不会导致公司控股股 东、实际控制人发生变化。 公司于 2025 年 6 月 6 日收到股东中移资本发来的《简式权益变动报告书》， 现将其本次权益变动情况公告如下： 一、本次权益变动基本情况 （一）信息披露义务人基本情况 投资管理；资产管理； ...

隆基绿能（601012）公告，截至本公告披露日，HHLR管理有限公司持有隆基绿能科技股份有限公司股 份4.16亿股，占公司总股本的5.50%。HHLR拟自公告披露之日起15个交易日后的3个月内，通过集中竞 价交易方式减持不超过3789.02万股，即不超过公司总股本的0.50%。减持期间，如公司总股本发生变 动，减持数量将相应调整。减持原因为基金投资运作需求。 ...

| 股东名称 | 咸持方式 | 减持期间 | 减持股数(股) | 占公司总股 本比例(%) | | --- | --- | --- | --- | --- | | 邹伟民 | 集中竞价 | 2025. 06. 04 | 1,112,800 | 0. 38% | | | 大宗交易 | 2025. 05. 29- | 2,223,717 | 0.77% | | 格通创投 | 集中竞价 | | 882,200 | 0. 30% | | | 大宗交易 | | 3,564,597 | 1.23% | | 陈敏 | | | - | 0. 00% | | | 合计 | | 7.783.314 | 2. 69% | 中国经济网北京6月6日讯传艺科技（002866）(002866.SZ)昨日晚间披露关于控股股东、实际控制人及其一致行动人持股比例变动触及1%及 5%整数倍暨披露简式权益变动报告书的提示性公告。 公司近日收到控股股东、实际控制人邹伟民及其一致行动人宁波格通创业投资合伙企业(有限合伙)以下简称("格通创投")出具的《简式权益 变动报告书》及《股份减持告知函》，获悉邹伟民及其一致行动人格通创投于2025年5月29日至6 ...

中信证券股份有限公司、中泰证券股份有限公司 关于乖宝宠物食品集团股份有限公司股东 向特定机构投资者询价转让股份 相关资格的核查意见 中信证券股份有限公司（以下简称"中信证券"）、中泰证券股份有限公司 （以下简称"中泰证券"）受乖宝宠物食品集团股份有限公司（以下简称"乖宝 宠物"）股东 Golden Prosperity Investment S.A.R.L.（以下简称"出让方"）委托， 组织实施本次乖宝宠物首发前股东向特定机构投资者询价转让（以下简称"本次 询价转让"）。 根据《上市公司股东减持股份管理暂行办法》《深圳证券交易所创业板股票 上市规则（2025 年修订）》《深圳证券交易所上市公司自律监管指引第 18 号— —股东及董事、高级管理人员减持股份（2025 年修订）》《深圳证券交易所上市 公司自律监管指引第 16 号——创业板上市公司股东询价和配售方式转让股份 （2025 年修订）》（以下简称"《询价转让和配售指引》"）等相关规定，中信 证券、中泰证券对参与本次询价转让股东的相关资格进行核查，并出具本核查意 见。 一、本次询价转让的委托 中信证券、中泰证券收到出让方关于本次询价转让的委托，委托中信证券 ...

Group 1 - The company, Lifan Pharmaceutical (stock code 003020), announced that several key personnel and shareholders plan to reduce their holdings in the company [1] - Board member Wang Qing intends to reduce his holdings by no more than 321,200 shares, accounting for 0.17% of the company's total share capital [1] - Supervisor Wang Qin plans to reduce his holdings by no more than 143,400 shares, representing 0.07% of the total share capital [1] - Senior management member Dai Tianhe aims to reduce his holdings by no more than 142,900 shares, also 0.07% of the total share capital [1] - Senior management member Zheng Yong plans to reduce his holdings by no more than 104,100 shares, which is 0.05% of the total share capital [1] - Shareholder Gao Meihua intends to reduce his holdings by no more than 300,000 shares, accounting for 0.16% of the total share capital [1] Group 2 - The reduction period for these shareholdings is set from June 30, 2025, to September 29, 2025, and from June 12, 2025, to September 11, 2025 [1] - The method of reduction will be through centralized bidding or block trading [1]

Core Viewpoint - The announcement reveals that Chen Rongfa, a director and senior executive of Sifang Jingchuang (300468), plans to reduce his shareholding in the company due to personal financial needs, involving a maximum of 276,300 shares, which represents 0.05% of the total share capital [1] Summary by Relevant Sections - **Shareholding Reduction Plan** - Chen Rongfa intends to reduce his holdings by up to 276,300 shares within three months following the announcement, through centralized bidding [1] - This reduction accounts for 0.05% of the company's total share capital [1] - **Reason for Reduction** - The reason for the share reduction is stated as personal financial needs [1] - **Source of Shares** - The shares to be reduced are sourced from the equity incentive plan granted to Chen Rongfa [1] - **Compliance and Disclosure** - Chen Rongfa will strictly adhere to relevant laws and regulations during the reduction process and will fulfill information disclosure obligations in a timely manner [1]

Core Viewpoint - The announcement details a significant share reduction by a major shareholder of Tuoxin Pharmaceutical, indicating a shift in ownership structure and potential implications for investor confidence [1][2]. Shareholding Changes - The controlling shareholder, Yang Xining, and his concerted action party, Yiwos Trading Co., Ltd., reduced their stake by 1,019,100 shares, representing 0.81% of the total share capital [1][2]. - Post-reduction, the combined shareholding of Yang Xining and Yiwos decreased from 28.80% to 27.99% [1]. Financial Performance - Tuoxin Pharmaceutical reported a revenue of 422 million yuan for the previous year, a decline of 49.53% year-on-year [2]. - The net profit attributable to shareholders was -19.88 million yuan, compared to a profit of 243 million yuan in the previous year [2]. - The net profit after deducting non-recurring gains and losses was -27.26 million yuan, down from 23.2 million yuan year-on-year [2]. - The net cash flow from operating activities was 103 million yuan, an increase of 280.91% year-on-year [2]. Recent Quarterly Results - In the first quarter of 2025, Tuoxin Pharmaceutical achieved a revenue of 96.99 million yuan, a decrease of 10.46% compared to the same period last year [3]. - The net profit attributable to shareholders was -3.56 million yuan, compared to a profit of 0.21 million yuan in the same quarter last year [3]. - The net cash flow from operating activities was 28.01 million yuan, a decline of 153.72% year-on-year [3]. Dividend Distribution - The board approved a profit distribution plan, proposing no cash dividends or stock bonuses for shareholders [3]. Initial Public Offering (IPO) Details - Tuoxin Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on October 27, 2021, with an initial public offering of 31.5 million shares at a price of 19.11 yuan per share [3]. - The total funds raised amounted to 602 million yuan, with a net amount of 543 million yuan after deducting issuance costs [3][4]. - The funds were intended for projects related to nucleoside series specialty raw materials, pharmaceutical intermediates, and working capital [3].

Core Viewpoint - Qingniao Fire Protection (002960.SZ) announced the completion of its shareholder's share reduction plan, with the controlling shareholder Beijing Peking University Qingniao Huan Yu Technology Co., Ltd. reducing 20 million shares within the specified period [1] Shareholder Reduction Details - The reduction was executed through concentrated bidding and block trading methods, with the total shares reduced amounting to 2,000,000 shares, representing a 2.72% reduction of the total shares [2] - The average reduction price was 11.23 CNY per share for 700,000 shares, 12.13 CNY for 1,146,800 shares, and 10.23 CNY for 153,200 shares [2] Financial Impact - The total cash generated from the share reduction was approximately 23,338,920 CNY [3] - Qingniao Fire Protection was listed on the Shenzhen Stock Exchange on August 9, 2019, with an initial public offering of 60 million shares at a price of 17.34 CNY per share, raising a total of 104,040,000 CNY [3] - The company conducted a private placement of 74,422,182 shares on November 3, 2022, at a price of 24.01 CNY per share, raising approximately 1,786,876,589.82 CNY [3] Profit Distribution Plans - For the 2021 fiscal year, the company proposed a cash dividend of 4.0 CNY per 10 shares, totaling 139,574,244.40 CNY, along with a capital reserve conversion increasing the total shares to 488,509,855 [4] - In 2020, the company distributed 4.489534 CNY per 10 shares in cash and converted capital reserves to increase shares by 3.990697 per 10 shares [4]